Dr. Kevin Wang is internationally recognized for his original contributions to the fields of traumatic brain injury (TBI)-linked proteolytic enzymes, therapeutic targets, neuroproteomics/systems biology, biomarker discovery and validation. Dr. Wang has published in the areas of systems biology/bioinformatics of biomarkers identification in with the main application on neural injury. In his quest for brain injury therapeutics, his omics/systems biology work has led to the identification of clinical diagnostic utility for two brain injury protein biomarkers during the acute phase of brain injury which have now been confirmed tested in clinical samples and are now moving forward to FDA-approval seeking pivotal clinical study. His current research directions include studying mechanisms for CNS injury, neuroproteomics, systems biology, and substance abuse-induced brain perturbation using systems biology approach. He has published more than 200 peer-reviewed papers, reviews and book chapters and co-authored eight US patents and co-edited four books. Dr. Wang is also past President (2011-12) and current Councilor (2013 - present) of the National Neurotrauma Society (USA).